Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25888929 | 0.90 | ALDH1A1 (0.36) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL14926138 | 0.89 | HTT (0.36) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL20400328 | 0.87 | HTT (0.38) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL31497515 | 0.87 | CYP1A2 (0.38) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL173687 | 0.87 | HTT (0.38) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL28126266 | 0.86 | CYP1A2 (0.38) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL28166589 | 0.80 | HTT (0.37) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL611899 | 0.79 | CHEK1 (0.36) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL25888930 | 0.78 | MEN1 (0.37) | HTTCYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL14926070 | 0.77 | LMNA (0.46) | HTTCYP1A2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055019-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2365970-A1 | Pyridazinones and their use as btk inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | HTT 4819/4885CYP1A2 1623/4885CYP2C19 382/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | HTT 554/4885CYP1A2 2089/4885CYP2C19 3145/4885 |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | HTT 3865/4885CYP1A2 1477/4885CYP2C19 1171/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | HTT 1446/4885CYP1A2 3742/4885CYP2C19 4026/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | HTT 3865/4885CYP1A2 1477/4885CYP2C19 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.